Clinical Trial: PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07133750) titled 'PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer' on July 30.

Brief Summary: PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: CRC (Colorectal Cancer)

Intervention: DRUG: PM8002

IV infusion

DRUG: Chemotherapy Regimen 1

IV infusion

DRUG: Chemotherapy Regimen 2

Oral administration and IV infusion

Recruitment Status: NOT_YET_RECRUITI...